Orano med

Orano Med is a clinical-stage biotech pioneering targeted alpha therapy (TAT) with lead-212, a highly potent but short-range alpha emitter designed to precisely destroy cancer cells while sparing healthy tissue. The company has built an integrated platform encompassing isotope production, preclinical development, and has initiated clinical trials. With operations in the US and France, Orano Med is positioning itself in the rapidly growing radioligand therapy market, aiming to address significant unmet needs in oncology.

Targeted Alpha Therapy (TAT) platform utilizing the alpha-emitting radioisotope lead-212 (212Pb) conjugated to tumor-targeting vectors (e.g., antibodies, peptides). The platform includes proprietary capabilities in industrial-scale 212Pb production.

Orano Med competes in the targeted radioligand therapy space against giants like Novartis (with approved beta therapies) and other biotechs developing alpha-emitting platforms (e.g., using Actinium-225). Its differentiation hinges on the specific properties of lead-212 and its integrated production capabilities.